Canada is heading to the polls on April 28 after a snap spring election was called by Prime Minister Mark Carney at the end ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

Individual researchers and university leaders need to make the case for science to their elected representatives and to the public at large.

Russia may face a new wave of drugs’ shortages, particularly those, which are used for the treatment of rare diseases, as ...

Vertex Pharmaceuticals today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has granted consent for the expanded use of ...

For years, my son grew up as a perfectly healthy kid, despite being diagnosed with CF-related metabolic syndrome. But when he suddenly developed pancreatitis, I had a hunch it was actually related to ...